Current stock page

Stock Analysis

Cogent Biosciences, Inc. (COGT) Stock Analysis

Cogent Biosciences, Inc. (COGT) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

COGT Stock Analysis Summary

Cogent Biosciences, Inc. (COGT) currently has an AIQ Score of 44/100, indicating a bearish setup. Risk is the strongest factor at 51/100. Quality is the weakest current factor at 40/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

COGT at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$28.56
AIQ Score44/100
Overall ViewBearish
Technical Analysis ConsensusStrong Sell
Market Cap$4.94B
P/E Ratio (TTM)-12.31
Forward P/E—
EPS (Q3 FY2026)-$0.59
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.38
Volume1.15M
52-week range$27.74-$43.73
RSI 1440.78
50-Day SMA$31.39
200-Day SMA$35.30
Analyst Price Target—
Next EarningsFeb 16, 2027
As of Nov 13, 2026 · Market close

COGTCogent Biosciences, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

BearishEdge 7/10
$28.56−$0.58 (−1.99%)

Latest quote

  • Momentum
    45
  • Value
    —
  • Quality
    40
  • Risk resilience
    51
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

COGT Stock Analysis Summary

Cogent Biosciences, Inc. (COGT) currently has an AIQ Score of 44/100, indicating a bearish setup. Risk resilience is the strongest factor at 51/100. Quality is the weakest current factor at 40/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, COGT has AIQ Score of 44/100 with Risk resilience base of 51/100 and fading Quality at 40/100. Wait for component alignment before adding exposure.

Healthcare · -1.99% stock move · COGT classified in Biotechnology.

Current Evidence

BearishCOGT is in a bearish AIQ regime; Risk resilience is the strongest visible factor at 51/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is COGT Bullish or Bearish Right Now?

COGT currently has a bearish overall setup. Risk Resilience is the strongest factor at 51/100, while Quality is weakest at 40/100. The current evidence suggests a bearish setup.

Bull Case
  • - No strong bullish evidence is available in the current snapshot.
Bear Case
  • - Momentum is weak at 45/100.
  • - Price is -19.10% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (34 vs 9).

Current Consensus

COGT's Technical Analysis Consensus is currently Strong Sell, with 9 buy, 3 neutral, and 34 sell votes. COGT's 14-day RSI is 40.78, which places the stock in a weaker momentum range. COGT's beta is 1.38, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in COGT?

The largest recent change in COGT is Momentum moving up by 3.0 points over the available 7-day comparison window. Risk Resilience remains the strongest visible factor.

AIQ Score
+2.0
Momentum
+3.0
Quality
+0.0
Risk
+2.0

What Would Change the COGT Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

COGT Decision Framework

Public evidence layers, setup checks, and risk context for Cogent Biosciences, Inc..

Cogent Biosciences, Inc. (COGT) Stock Analysis

Cogent Biosciences, Inc. has an AIQ Score of 44/100 in a Bearish regime. Risk is strongest at 51/100. Beta is 1.38, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextCOGT is in a Bearish AIQ regime with score 44/100.
Signal ConflictThe primary conflict is that risk leads at 51/100 while quality lags at 40/100.
Factor EvidenceMomentum 45/100 · Quality 40/100 · Risk 51/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Risk is the strongest factor at 51/100.

TimingFail

Momentum is 45/100 and RSI (14) is 40.8.

Regime fitFail

COGT is in a Bearish regime at 44/100.

Risk controlWait

Risk factor is 51/100 with beta 1.38 and annual volatility 45.96%.

ConflictPass

Current conflict: risk leads at 51/100 while quality lags at 40/100.

AIQ Score
44/100
Price
$28.56
Beta
1.38
RSI (14)
40.8

COGT Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

COGT Fundamentals

COGT valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$111.43M
Free cash flow
-$80.9M
View full COGT fundamental analysis

COGT Technical Analysis

COGT technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
40.78
Price vs SMA-50
-9.02%
View full COGT technical analysis

COGT Stock Catalysts

Track COGT earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 16, 2027
Analyst target
—
News items
3
View COGT earnings and stock catalysts

COGT Dividend Analysis

COGT dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View COGT dividend history and analysis

COGT Financial Data

COGT revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.59
Periods
8
View COGT financials

COGT Risk Analysis

COGT volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.38
Risk score
51/100
1Y volatility
45.96%
View COGT risk analysis

COGT Stock News

COGT stock news, market tone, recent headlines, and catalyst context.

News items
3
Updated
Nov 15, 2026
Sentiment
—
Read COGT stock news

COGT vs Biotechnology Peers

Current peer cohort: COGT · CYTK · DFTX · DNTH · DYN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
COGT
Current stock
44/100—45/10051/100-0.2345.96%Current
CYTK
Cytokinetics, Incorporated
40/10041/10028/10056/100-0.2343.65%COGT vs CYTK
DFTX
Definium Therapeutics, Inc.
59/100—64/10044/1001.6177.71%COGT vs DFTX
DNTH
Dianthus Therapeutics, Inc.
56/100—58/10058/1001.8259.79%COGT vs DNTH
DYN
Dyne Therapeutics, Inc.
48/100—52/10042/1000.1163.89%COGT vs DYN
Pairwise Compare links: CYTK · DFTX · DNTH · DYNCOGT vs CYTKCOGT vs DFTXCOGT vs DNTHCOGT vs DYNCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a COGT stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for COGT: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-12.31
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0.47
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$111.43M
Quarter free cash flow
-$80.9M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Bearish
RSI 14
40.78
MACD
-0.43

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
51/100
Beta
1.38
Annual volatility
45.96%
Max drawdown
-34.43%

COGT Stock FAQ

What is COGT stock price today?

Cogent Biosciences, Inc.'s current stock price is $28.56. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is COGT bullish or bearish right now?

COGT's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is COGT's market cap?

COGT's market cap is $4.94B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is COGT's current P/E ratio?

COGT's current P/E ratio is -12.31 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is COGT's RSI?

COGT's 14-day RSI is 40.78 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is COGT above its 50-day and 200-day moving averages?

COGT is -9.02% from its 50-day SMA and -19.10% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is COGT's next earnings date?

COGT's next earnings date is currently listed as Feb 16, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does COGT pay a dividend?

COGT's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.